310 related articles for article (PubMed ID: 27846613)
21. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
22. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
[TBL] [Abstract][Full Text] [Related]
24. Update on the management of primary CNS lymphoma.
Nasir S; DeAngelis LM
Oncology (Williston Park); 2000 Feb; 14(2):228-34; discussion 237-42, 244. PubMed ID: 10736810
[TBL] [Abstract][Full Text] [Related]
25. Primary renal diffuse large B-cell lymphoma with central nervous system involvement: a rare case report and literature review.
Wang Y; Guo S
Int J Clin Exp Pathol; 2015; 8(6):7045-9. PubMed ID: 26261597
[TBL] [Abstract][Full Text] [Related]
26. Prevention of CNS relapse in diffuse large B-cell lymphoma.
Kridel R; Dietrich PY
Lancet Oncol; 2011 Dec; 12(13):1258-66. PubMed ID: 21933751
[TBL] [Abstract][Full Text] [Related]
27. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
28. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Sancho JM; Ribera JM;
Med Clin (Barc); 2016 Jan; 146(2):74-80. PubMed ID: 25817451
[TBL] [Abstract][Full Text] [Related]
29. Primary lymphoma of the central nervous system.
Singh AD; Lewis H; Schachat AP
Ophthalmol Clin North Am; 2005 Mar; 18(1):199-207, x. PubMed ID: 15763205
[TBL] [Abstract][Full Text] [Related]
30. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers.
Ryan GF; Roos DR; Seymour JF
Clin Lymphoma Myeloma; 2006 Jan; 6(4):337-41. PubMed ID: 16507213
[TBL] [Abstract][Full Text] [Related]
31. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
32. Central nervous system involvement of primary cutaneous diffuse large B cell lymphoma-leg type diagnosed according to the WHO 2008 classification.
Aoki K; Arima H; Tabata S; Matsushita A; Ishikawa T; Takahashi T
Ann Hematol; 2012 Dec; 91(12):1975-6. PubMed ID: 22592652
[No Abstract] [Full Text] [Related]
33. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
Bierman P; Giglio P
Hematol Oncol Clin North Am; 2005 Aug; 19(4):597-609, v. PubMed ID: 16083825
[TBL] [Abstract][Full Text] [Related]
34. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989.
Miller DC; Hochberg FH; Harris NL; Gruber ML; Louis DN; Cohen H
Cancer; 1994 Aug; 74(4):1383-97. PubMed ID: 8055462
[TBL] [Abstract][Full Text] [Related]
35. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
36. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.
Lehners N; Krämer I; Schwarzbich MA; Ho AD; Witzens-Harig M
Leuk Lymphoma; 2016 Nov; 57(11):2619-25. PubMed ID: 26999040
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Lee MY; Kim HS; Lee JY; Lim SH; Kang ES; Ko YH; Kim SJ; Kim WS
Int J Hematol; 2015 Dec; 102(6):678-88. PubMed ID: 26493833
[TBL] [Abstract][Full Text] [Related]
38. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?
Siegal T; Goldschmidt N
Blood Rev; 2012 May; 26(3):97-106. PubMed ID: 22244544
[TBL] [Abstract][Full Text] [Related]
39. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
Laskin JJ; Savage KJ; Voss N; Gascoyne RD; Connors JM
Leuk Lymphoma; 2005 Dec; 46(12):1721-7. PubMed ID: 16263574
[TBL] [Abstract][Full Text] [Related]
40. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
O'Rourke K; Morris K; Kennedy GA
Cancer; 2011 Jun; 117(11):2579-80; author reply 2580-1. PubMed ID: 24048807
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
